Calliditas Spies Chinese Market As Tarpeyo Continues Upwards Sales Curve
IgAN Therapy Advancing In US
Executive Summary
The Swedish biotech’s successful launch in the US of Tarpeyo for immunoglobulin A nephropathy is progressing well and a Chinese approval is on the horizon as partner Everest’s application is accepted by regulators.
You may also be interested in...
Calliditas Eyes Full Approval For Tarpeyo In IgAN After Positive Pivotal Update
Data from part B of the Swedish firm’s pivotal trial of Tarpeyo in the rare kidney disorder showed that the treatment effects lasted two years across the entire population, enabling the move from conditional to full approvals in several markets.
Calliditas Confident Of Keeping Ahead Of Travere In IgAN
The Swedish group’s Tarpeyo is reaping the benefits of an expanded US sales force and the company is confident of a big revenue rise in 2023, regardless of new competition in the IgAN field from Travere’s Filspari.
Travere’s Filspari US Approval Marks First For IgAN
Travere Therapeutics is aiming to provide a new foundational therapy for IgAN patients with its novel non-immunosuppressive agent, Filspari, as it prices it at a discount to Calliditas’s rival Tarpeyo, ahead of looming further competition.